Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Down 17.6% in December

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a large drop in short interest in December. As of December 31st, there was short interest totaling 11,149,487 shares, a drop of 17.6% from the December 15th total of 13,528,238 shares. Currently, 14.0% of the company’s stock are short sold. Based on an average trading volume of 11,616,018 shares, the days-to-cover ratio is presently 1.0 days. Based on an average trading volume of 11,616,018 shares, the days-to-cover ratio is presently 1.0 days. Currently, 14.0% of the company’s stock are short sold.

Aspire Biopharma Stock Up 2.7%

Shares of Aspire Biopharma stock traded up $0.06 on Tuesday, reaching $2.27. The company’s stock had a trading volume of 1,303,965 shares, compared to its average volume of 1,982,595. Aspire Biopharma has a 52 week low of $1.65 and a 52 week high of $632.00. The firm’s fifty day simple moving average is $3.99 and its two-hundred day simple moving average is $11.68. The company has a market capitalization of $6.10 million, a price-to-earnings ratio of -4.54 and a beta of 0.81.

Aspire Biopharma (NASDAQ:ASBP) last released its quarterly earnings data on Friday, November 14th. The company reported ($1.60) EPS for the quarter. The company had revenue of $0.00 million during the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ASBP. Optivise Advisory Services LLC boosted its position in shares of Aspire Biopharma by 120.9% in the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after purchasing an additional 128,660 shares during the period. Jane Street Group LLC lifted its position in shares of Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after buying an additional 131,533 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Aspire Biopharma during the 3rd quarter worth approximately $28,000. Finally, Crewe Advisors LLC boosted its position in shares of Aspire Biopharma by 100.0% during the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after acquiring an additional 313,427 shares during the last quarter. Hedge funds and other institutional investors own 19.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ASBP shares. Weiss Ratings restated a “sell (e+)” rating on shares of Aspire Biopharma in a report on Wednesday, October 8th. Wall Street Zen raised Aspire Biopharma to a “sell” rating in a research note on Saturday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.